Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis

BACKGROUND: We evaluated organ-specific response rates (OSRRs) to first-line lenvatinib plus anti-PD-1 antibodies in patients with advanced hepatocellular carcinoma (HCC). METHODS: This retrospective analysis included Chinese patients with unresectable/advanced HCC who received first-line lenvatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Cheng, Zhu, Xiao-Dong, Shen, Ying-Hao, Wu, Dong, Ji, Yuan, Ge, Ning-Ling, Chen, Ling-Li, Tan, Chang-Jun, Zhou, Jian, Fan, Jia, Sun, Hui-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981986/
https://www.ncbi.nlm.nih.gov/pubmed/33743822
http://dx.doi.org/10.1186/s40364-021-00274-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981986/
https://www.ncbi.nlm.nih.gov/pubmed/33743822
http://dx.doi.org/10.1186/s40364-021-00274-z

Ejemplares similares